Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Labor, Induced | 12 | 2023 | 25 | 4.260 |
Why?
|
| Oxytocics | 7 | 2022 | 14 | 3.480 |
Why?
|
| Cervical Ripening | 7 | 2021 | 11 | 2.450 |
Why?
|
| Pre-Eclampsia | 4 | 2023 | 71 | 2.110 |
Why?
|
| Oxytocin | 4 | 2021 | 45 | 1.990 |
Why?
|
| Misoprostol | 4 | 2020 | 9 | 1.920 |
Why?
|
| Postpartum Hemorrhage | 3 | 2023 | 6 | 1.740 |
Why?
|
| Pregnancy | 28 | 2023 | 2335 | 1.720 |
Why?
|
| Cesarean Section | 5 | 2023 | 101 | 1.210 |
Why?
|
| Delivery, Obstetric | 2 | 2020 | 52 | 1.190 |
Why?
|
| Cervix Uteri | 2 | 2020 | 60 | 1.110 |
Why?
|
| Chorioamnionitis | 3 | 2023 | 14 | 1.050 |
Why?
|
| Premature Birth | 5 | 2022 | 112 | 1.030 |
Why?
|
| Endometritis | 2 | 2023 | 4 | 1.020 |
Why?
|
| Hypertension, Pregnancy-Induced | 3 | 2023 | 40 | 1.010 |
Why?
|
| Catheters | 3 | 2022 | 75 | 0.990 |
Why?
|
| Urinary Catheterization | 3 | 2021 | 21 | 0.900 |
Why?
|
| Polyhydramnios | 1 | 2023 | 2 | 0.850 |
Why?
|
| Eclampsia | 1 | 2021 | 3 | 0.730 |
Why?
|
| Prenatal Care | 3 | 2020 | 170 | 0.710 |
Why?
|
| Dinoprostone | 1 | 2020 | 43 | 0.650 |
Why?
|
| Infant, Newborn | 11 | 2023 | 1358 | 0.650 |
Why?
|
| Female | 29 | 2023 | 32883 | 0.640 |
Why?
|
| Cerclage, Cervical | 2 | 2020 | 4 | 0.630 |
Why?
|
| Private Practice | 1 | 2015 | 12 | 0.490 |
Why?
|
| Pregnancy, Multiple | 1 | 2014 | 10 | 0.460 |
Why?
|
| Smoke-Free Policy | 1 | 2014 | 9 | 0.460 |
Why?
|
| Pregnancy in Adolescence | 1 | 2014 | 21 | 0.450 |
Why?
|
| Ambulatory Care | 1 | 2017 | 311 | 0.450 |
Why?
|
| Genetic Testing | 1 | 2015 | 134 | 0.450 |
Why?
|
| Humans | 29 | 2023 | 63449 | 0.440 |
Why?
|
| Anaphylaxis | 1 | 2014 | 39 | 0.430 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 317 | 0.420 |
Why?
|
| Guideline Adherence | 1 | 2015 | 305 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 772 | 0.330 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 712 | 0.320 |
Why?
|
| Retrospective Studies | 7 | 2023 | 6659 | 0.320 |
Why?
|
| Maternal Age | 1 | 2009 | 33 | 0.320 |
Why?
|
| Maternal Mortality | 1 | 2009 | 13 | 0.320 |
Why?
|
| Adult | 13 | 2022 | 16826 | 0.320 |
Why?
|
| Administration, Intravaginal | 3 | 2019 | 12 | 0.290 |
Why?
|
| Progestins | 3 | 2022 | 29 | 0.290 |
Why?
|
| Gestational Age | 3 | 2023 | 189 | 0.280 |
Why?
|
| Progesterone | 2 | 2022 | 163 | 0.280 |
Why?
|
| Young Adult | 6 | 2020 | 4695 | 0.270 |
Why?
|
| Catheterization | 2 | 2018 | 111 | 0.270 |
Why?
|
| Time Factors | 4 | 2020 | 3768 | 0.230 |
Why?
|
| Pregnancy Complications | 1 | 2009 | 378 | 0.230 |
Why?
|
| Watchful Waiting | 1 | 2023 | 29 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 790 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 724 | 0.200 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2020 | 81 | 0.190 |
Why?
|
| Traction | 1 | 2022 | 5 | 0.190 |
Why?
|
| Masks | 1 | 2022 | 23 | 0.190 |
Why?
|
| Magnesium Sulfate | 1 | 2021 | 9 | 0.180 |
Why?
|
| Family | 1 | 2023 | 237 | 0.180 |
Why?
|
| Philadelphia | 2 | 2020 | 21 | 0.180 |
Why?
|
| Pregnancy Trimester, First | 2 | 2020 | 25 | 0.170 |
Why?
|
| RNA, Viral | 1 | 2022 | 276 | 0.170 |
Why?
|
| Milk, Human | 1 | 2022 | 90 | 0.170 |
Why?
|
| Perinatal Mortality | 1 | 2020 | 2 | 0.170 |
Why?
|
| Tocolytic Agents | 1 | 2020 | 3 | 0.170 |
Why?
|
| Pregnancy, Twin | 1 | 2020 | 5 | 0.170 |
Why?
|
| Labor Stage, First | 1 | 2020 | 7 | 0.170 |
Why?
|
| Apgar Score | 1 | 2020 | 11 | 0.170 |
Why?
|
| Anesthesia, Epidural | 1 | 2020 | 24 | 0.170 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 49 | 0.160 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 209 | 0.160 |
Why?
|
| Hydroxyprogesterones | 2 | 2022 | 6 | 0.160 |
Why?
|
| Breast Feeding | 1 | 2022 | 151 | 0.160 |
Why?
|
| Cervical Length Measurement | 2 | 2020 | 6 | 0.160 |
Why?
|
| Erythromycin | 1 | 2019 | 4 | 0.150 |
Why?
|
| Uterine Hemorrhage | 1 | 2019 | 20 | 0.150 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2019 | 12 | 0.150 |
Why?
|
| Parity | 2 | 2018 | 71 | 0.150 |
Why?
|
| Azithromycin | 1 | 2019 | 32 | 0.150 |
Why?
|
| Mothers | 1 | 2022 | 275 | 0.150 |
Why?
|
| Aspirin | 1 | 2020 | 171 | 0.150 |
Why?
|
| Arterial Pressure | 1 | 2018 | 26 | 0.150 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 226 | 0.140 |
Why?
|
| Depression, Postpartum | 1 | 2020 | 129 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2020 | 3293 | 0.140 |
Why?
|
| Cytokines | 1 | 2022 | 935 | 0.140 |
Why?
|
| Pregnancy Outcome | 2 | 2018 | 194 | 0.140 |
Why?
|
| Delaware | 1 | 2017 | 8 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 205 | 0.130 |
Why?
|
| Abortion, Habitual | 1 | 2016 | 8 | 0.130 |
Why?
|
| New Jersey | 1 | 2015 | 26 | 0.120 |
Why?
|
| Pain | 1 | 2018 | 406 | 0.120 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 61 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2015 | 201 | 0.110 |
Why?
|
| Risk Factors | 3 | 2016 | 5354 | 0.110 |
Why?
|
| Administration, Buccal | 1 | 2014 | 2 | 0.110 |
Why?
|
| Hypertension | 1 | 2020 | 586 | 0.110 |
Why?
|
| Adolescent | 2 | 2015 | 6245 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2022 | 2570 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 536 | 0.100 |
Why?
|
| Depression | 1 | 2020 | 894 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 641 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 462 | 0.100 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2009 | 33 | 0.080 |
Why?
|
| United States | 3 | 2020 | 7843 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2017 | 5680 | 0.080 |
Why?
|
| Proteomics | 2 | 2022 | 283 | 0.080 |
Why?
|
| Middle Aged | 3 | 2022 | 17615 | 0.070 |
Why?
|
| Diabetes, Gestational | 1 | 2009 | 140 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 298 | 0.070 |
Why?
|
| Massachusetts | 2 | 2023 | 2075 | 0.060 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2022 | 3 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 208 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 96 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2020 | 6 | 0.040 |
Why?
|
| Birth Intervals | 1 | 2020 | 2 | 0.040 |
Why?
|
| Gynecological Examination | 1 | 2020 | 6 | 0.040 |
Why?
|
| Indomethacin | 1 | 2020 | 22 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 311 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2020 | 36 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 459 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2020 | 135 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 327 | 0.040 |
Why?
|
| Amoxicillin | 1 | 2019 | 8 | 0.040 |
Why?
|
| Dilatation | 1 | 2019 | 32 | 0.040 |
Why?
|
| Ampicillin | 1 | 2019 | 12 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 362 | 0.040 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2019 | 12 | 0.040 |
Why?
|
| Hematocrit | 1 | 2018 | 34 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2020 | 379 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 168 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 345 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 864 | 0.030 |
Why?
|
| Infant | 1 | 2022 | 1645 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 141 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2018 | 195 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 1408 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1377 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 418 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 812 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 768 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2018 | 429 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2016 | 2079 | 0.020 |
Why?
|